Introduction
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Produced in collaboration with Melanoma Research Foundation and Melanoma Action Coalition
Treatment options for patients with metastatic melanoma have expanded beyond surgery in recent years to include non-surgical options, such as immunotherapies and their combinations, leading to improved outcomes and better quality of life for patients.
Join an expert panel of dermatology and oncology specialists for a one-hour online presentation: “Partnering with Your Team to Select Treatment for Newly Diagnosed Melanoma.” Panelists will help patients and caregivers understand how new immunotherapy combinations work, side effects associated with treatment, and strategies that can help maintain quality of life. Patients will also be empowered to communicate with their healthcare team and participate confidently in their own care.
Learning Objectives:
- Discuss patients’ questions and concerns about new and emerging immunotherapies for advanced melanoma
- Outline the side effects patients can expect during treatment and how they can participate in minimizing those effects
- Discuss the importance of optimal collaboration between the members of the multidisciplinary care team, including patients, to improve outcomes
Hear from two patients speak about their journeys with surgical treatment of melanoma and you will understand why exploring non-surgical treatment options is worth exploring.
Register to watch anytime on demand.
Chapters
-
-
Setting the Stage
-
Who is on Your Treatment Team?
-
Treatment Options for Newly Diagnosed Patients
Speakers
Omid Hamid, MD
Evan Lipson, MD
Melissa Moore
Monique Mack
Omid Hamid, MD
Chief of Research/Immuno-Oncology
The Angeles Clinic & Research Institute
Co-Director, Cutaneous Malignancy Program
Cedars-Sinai Cancer
Omid Hamid, MD, is Chief, Translational Research and Immunotherapy and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute. As Director, he works to ensure that patients receive access to the most up-to-date therapeutics. Dr. Hamid’s research focus involves manipulation of a patient’s immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies. His research began in melanoma and has now extended into paradigm shifting trials for all cancers. Recently, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. Furthermore, he is recognized internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics.
Evan Lipson, MD
Associate Professor, Medical Oncology
Bloomberg-Kimmel Institute for Cancer Immunotherapy Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine
Evan Lipson, MD, is a cutaneous oncology and clinical immunotherapy specialist and Associate Professor of Oncology at Johns Hopkins. Dr. Lipson's primary research interest is in translational clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer and the first description of kidney retransplantation performed after anti–PD-1–related allograft rejection. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy.
Melissa Moore
Interview Participant, Melanoma cancer survivor
Monique Mack
Interview Participant, Melanoma cancer survivor
-
Omid Hamid, MD
Chief of Research/Immuno-Oncology
Omid Hamid, MD, is Chief, Translational Research and Immunotherapy and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute. As Director, he works to ensure that patients receive access to the most up-to-date therapeutics. Dr. Hamid’s research focus involves manipulation of a patient’s immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies. His research began in melanoma and has now extended into paradigm shifting trials for all cancers. Recently, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. Furthermore, he is recognized internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics.
The Angeles Clinic & Research Institute
Co-Director, Cutaneous Malignancy Program
Cedars-Sinai Cancer -
Evan Lipson, MD
Associate Professor, Medical Oncology
Evan Lipson, MD, is a cutaneous oncology and clinical immunotherapy specialist and Associate Professor of Oncology at Johns Hopkins. Dr. Lipson's primary research interest is in translational clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer and the first description of kidney retransplantation performed after anti–PD-1–related allograft rejection. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy.
Bloomberg-Kimmel Institute for Cancer Immunotherapy Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine -
Melissa Moore
Interview Participant, Melanoma cancer survivor
-
Monique Mack
Interview Participant, Melanoma cancer survivor
